Navigation Links
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Date:2/10/2010

OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, today announced that it has completed an oversubscribed GBP2.7 million ($4.3 million) investment round. The fundraising was supported by a number of existing institutional and private investors, including Hygea VCT and Oxford Technology VCTs. The company has now completed four successful investment rounds, securing funding totalling approximately GBP10 million. Glide will use the new funds to progress its in-house Glide octreotide programme into clinical development and to continue scale-up of its commercial manufacturing process.

The investment follows the recent successful clinical proof-of-concept of Glide Pharma's proprietary solid dose injector, the Glide SDI(R). The clinical study, conducted in 18 subjects with a solid dose formulation of the analgesic fentanyl, confirmed that the Glide SDI can safely and quickly deliver accurate doses into the systemic circulation, demonstrating the potential of the Glide technology in the $2 billion per annum breakthrough pain market. Throughout the study, administration with the needle-free Glide SDI avoided the bruising and bleeding associated with needle and syringe delivery.

"The completion of this oversubscribed fundraising is a clear demonstration of our investors' confidence in the Glide technology and the advantages it can offer both patients and our partners in the pharmaceutical industry," said Dr Charles Potter, Glide Pharma's CEO. "Glide has made great progress recently, having achieved clinical proof-of-concept with our proprietary solid dose injection system, and extending our pipeline of programmes with pharmaceutical partners. We aim to build on this strong foundation in the coming months by accelerating our second in-house project, Glide octreotide, into the clinic."

About Glide Pharma

Glide Pharma is a specialty pharmaceutical company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines. The company has a range of in-house and partnered programmes based on its proprietary needle-free solid dose injector, the Glide SDI(R).

Glide has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. The company has successfully completed four investment rounds, and is supported by a consortium of institutional and private technology investors, including Oxford Capital Partners, Hygea VCT and Oxford Technology Venture Capital Trusts.

About the Glide SDI(R) solid dose injector

The Glide SDI is an innovative needle-free delivery system. The reusable injector utilises a spring mechanism to rapidly administer medicines, in the form of a tiny granule supplied in a pre-filled disposable cassette, below the patient's skin where it dissolves and enters the circulation.

The one-click action, pen-sized device is extremely easy to use, making it ideal for self administration. In clinical testing, volunteers strongly preferred the Glide SDI to the traditional needle and syringe. Additionally, Glide solid dose formulations offer the potential to improve the stability and to modify the release of medicines into the bloodstream, avoid time-consuming reconstitution and eliminate the risk of needle-stick injuries.

    Contacts

    Charles Potter
    CEO
    Glide Pharma Tel:
    Tel: +44(0)8700-853700

    Rob Budge
    RJB Communications
    +44(0)1865-760969
    Mobile: +44(0)7710-741241


    http://www.glidepharma.com

SOURCE Glide Pharma


'/>"/>
SOURCE Glide Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verathon Introduces the GlideScope(R) Cobalt Advanced Video Laryngoscope (AVL); New Digital Technology Facilitates Quick Intubations
2. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
3. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
4. ISTA Pharmaceuticals Announces 2010 Financial Guidance
5. DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv
6. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
7. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
8. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
9. Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
10. Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
11. Babson Executive Education Offers Bio-Pharma: Mastering the Business of Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
Breaking Medicine News(10 mins):